Navigation Links
Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (, showed that when combined with standard anti-leukemia agents, the biological activity of LeukotheraTM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining LeukotheraTM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone.  LeukotheraTM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said.  "The biological mechanism of LeukotheraTM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop LeukotheraTM as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

"We provided early seed funding to Actinobac because we are convinced that they are working on breakthrough research that can make a huge difference for people suffering with leukemia and other diseases," said James M. Golubieski, president of Foundation Venture Capital Group (, an affiliate of New Jersey Health Foundation.  

For more information about Foundation Venture Capital Group, contact Jim Golubieski at (908) 731-6601 or

For more information or to explore ways in which to partner with Actinobac, contact them at (732) 371-2694, or visit

SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
3. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
4. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
5. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
6. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. In a New Audio Interview at, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... ... 26, 2015 , ... Somu Sivaramakrishnan announced today that he ... now offers travelers, value and care based Travel Services, including exclusive pricing on ... as, cabin upgrades and special amenities such as, shore excursions, discounted fares, travel ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... health and wellness consultation, has collaborated with Women’s Web – an online ... queries on topics on mental and emotional well-being relationship, life balance, stress, ...
Breaking Medicine News(10 mins):